

HR 4376

USTRx Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Foreign Trade and International Finance

Introduced: Jul 9, 2021

Current Status: Referred to the Subcommittee on Trade.

Latest Action: Referred to the Subcommittee on Trade. (Jul 9, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/4376>

Sponsor

Name: Rep. Arrington, Jodey C. [R-TX-19]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred to	Jul 9, 2021

Subjects & Policy Tags

Policy Area:

Foreign Trade and International Finance

Related Bills

No related bills are listed.

Summary (as of Jul 9, 2021)

Use Sovereignty To reduce Rx Act or the USTRx Act

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative (USTR) to conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

Actions Timeline

- **Jul 9, 2021:** Introduced in House
- **Jul 9, 2021:** Referred to the House Committee on Ways and Means.
- **Jul 9, 2021:** Referred to the Subcommittee on Trade.